天津发展(00882)：力生制药前三季度归母净利润3.71亿元 同比增加119.05%

Core Viewpoint - Tianjin Development (00882) reported a mixed financial performance for its indirect non-wholly owned subsidiary, Tianjin Lisheng Pharmaceutical Co., Ltd., with a slight decline in revenue but a significant increase in net profit [1] Financial Performance - Total revenue for the nine months ending September 30, 2025, was 1.007 billion yuan, representing a year-on-year decrease of 1.61% [1] - Net profit attributable to the parent company's owners was 371 million yuan, showing a year-on-year increase of 119.05% [1] - Basic earnings per share stood at 1.44 yuan [1]